Alnylam has led the translation of RNAi (RNA interference) from Nobel Prize-winning discovery into an innovative, entirely new class of medicines. Founded in 2002 by a team of distinguished life sciences leaders, Alnylam’s vision is to harness the potential of RNAi therapeutics to transform the lives of people living with diseases for which there are limited or inadequate treatment options. Our pioneering work has delivered the world’s first and only approved RNAi therapeutics—ONPATTRO® (patisiran) in 2018, GIVLAARI® (givosiran) in 2019, OXLUMO® (lumasiran) in 2020, and AMVUTTRA® (vutrisiran) in 2022. We are advancing a deep pipeline of innovative RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases.
AL-NY-LAM. Our name may not be the easiest to pronounce, but once you learn it, you’ll never forget it. Alnylam is derived from “Alnilam,” the bright center star in the constellation Orion’s belt, which has been used by navigators for thousands of years and symbolizes our passion for discovery.
Medicines based on RNAi work by “silencing” or disabling the production (“expression”) of the genes that cause specific diseases. In doing so, RNAi therapeutics work “upstream” of most other classes of medicines, such as small molecules and monoclonal antibodies, by targeting the “root” genetic cause of a disease rather than its symptoms. To learn more about our science, click here.
RNAi is the core discovery that forms the therapies Alnylam is developing. It is recognized as a major scientific breakthrough—but how does it work, exactly?
At Alnylam, we are driven by our mission to translate the Nobel Prize-winning discovery of RNA interference (RNAi) into an innovative, new class of medicines. We’re motivated in this endeavor by the bravery and perseverance of people with unmet medical needs who live with rare and genetic diseases. They are the focus of our efforts, and we exist as a company because of them. That knowledge and commitment to patients is present in everything we do, every day.
Our goal, which is well underway, is to become a world-class biopharmaceutical company that can independently develop and deliver innovative medicines based on RNAi to patients worldwide. We have a deep pipeline of early to late stage investigational therapies, and 2018 marked the approval of our first medicine—the world’s first RNAi therapeutic. Even though we’ve been around since 2002, we’re just getting started!
We are growing quickly and hiring across North America, Europe, Asia, and Latin America for a wide variety of roles. We’re seeking smart, passionate, “change the world” kind of people who are ready to say, “challenge accepted.” Our 1,500 (and counting!) employees are building a diverse, equitable, inclusive, and high-performing global organization that celebrates team achievement and recognizes individual contributions.
We’re at the forefront of what’s next for patients, and perhaps your career also.